Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-634-0 | CAS number: 123-54-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Neurotoxicity
Administrative data
- Endpoint:
- neurotoxicity: short-term dermal
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Materials and methods
- Principles of method if other than guideline:
- New Zealand White rabbits were treated by 6 h occluded cutaneous application with undiluted 2,4-pentanedione at dose volumes of 0.25, 1.0 and 1.5 mL/kg bw. Animals in the control group received occluded applications of Milli-Q filtered water at a volume of 1.5 mL/kg bw. The test or control substance was applied to the clipped dorsal surface of the rabbits. Twelve animals/sex/group were used for the control and high dose groups, 6 animals/sex/group for mid and low dose groups. The original study design included dosing for 5 days the first week and 4 day the second week. The additional 6 animals/sex/group in the controls and the high dose group were used for a 4 week recovery period. Due to mortality and signs of toxicity observable in mid and high dose groups, dosing was discontinued for these groups after day 4. Three surviving males and 2 surviving females from the 1463 mg/kg bw group were euthanized on day 4 while an additional 4 males and 3 females were retained without further dosing to day 12. Rabbits in the low dose group continued to receive a total of 9 doses (5 in the first week, 4 in the second). On day 12, 6 rabbits/sex from the control group were removed from the study since they were not required for their intended purpose as a recovery group. All other surviving rabbits were euthanized on day 12. Only 3 rabbits/sex from the control group were subjected to necropsy and histopathology. Monitors for toxicity included observations for clinical signs, including skin irritation, food consumption, water consumption, body weight and body weight change, organ weights, gross pathology and histopathology.
- GLP compliance:
- yes
Test material
- Details on test material:
- Purity: >98%
Lot No.: 0335033-007
Physical state: liquid
Storage: room temperature
Constituent 1
Test animals
- Species:
- rabbit
- Strain:
- New Zealand White
- Sex:
- male/female
Administration / exposure
- Route of administration:
- dermal
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- TEST MATERIAL
- Amounts applied: 0.25, 1, and 1.5 mL
- Constant volume or concentration used: no
TEST SITE
- Area of exposure:
- % coverage:
- Type of wrap if used: gauze pads
- Time intervals for shavings or clipplings:
REMOVAL OF TEST SUBSTANCE
- Washing: After exposure the back of the animal was wiped with a damp cloth.
- Time after start of exposure:
TEST MATERIAL
- Amount(s) applied (volume or weight with unit):
- Concentration (if solution):
- Constant volume or concentration used: yes/no
- For solids, paste formed: yes/no - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 9 days
- Frequency of treatment:
- Once daily (5 days first week, 4 days second week)
Doses / concentrations
- Remarks:
- Doses / Concentrations:
244, 975 and 1463 mg/kg bw
Basis:
nominal conc.
- No. of animals per sex per dose:
- 6
- Control animals:
- yes
Examinations
- Observations and clinical examinations performed and frequency:
- Monitors for toxicity included observations for clinical signs, including skin irritation, food consumption, water consumption, body weight and body weight change, and organ weights.
- Sacrifice and (histo)pathology:
- 3 rabbits/sex from the control group were subjected to necropsy and histopathology. Monitors for toxicity included observations for clinical signs, including skin irritation, food consumption, water consumption, body weight and body weight change, organ weights, gross pathology and histopatholog
Results and discussion
Results of examinations
- Details on results:
- Occluded cutaneous dosing of rabbits with 2,4-pentanedione for 3 or 4 days resulted in death of 5/12 males and 7/12 females in the 1.5 mL/kg (1463 mg/kg) group and 1/6 males and 3/6 females in the 1.0 mL/kg (975 mg/kg) group. In the mid and high dose groups of rabbits during the first few days of the study, several signs of systemic toxicity were evident. Numerous animals from these dose groups were hypoactive, uncoordinated and/or prostrate, had tremors, salivation, gasping and/or convulsions, and some had blue cutis of the nasal area suggestive of cyanosis. Gross and microscopic evaluation at both day 4 and 12 confirmed dose-related skin irritation in all treatment groups. Microscopic lesions included acanthosis, subcutaneous edema, dermatitis, hemorrhage, congestion and/or necrosis. There were also numerous rabbits with hemorrhaging in various sections of the brain, including the meninges. Additionally, a number of brain sections showed neuronal degeneration, including the hypothalamus, mid brain, piriform cortex, pons and/or hippocampus. At both day 4 and 12, the thymus or thymic region, spleen, and/or lymph nodes of several animals of both sexes from the mid and high dose groups were congested and/or hemorrhaged; some animals also had lymphoid depletion or necrosis. This observation, combined with decreased lymphocyte and eosinophil counts in the high dose group at day 4, suggested possible effects on the immune system. Since the animals from the mid and high dose group had severe skin irritation and many signs of systemic effects a definitive conclusion regarding a treatment related response to the immune system is not possible, as discussed by the study authors. Except clinical pathology changes that may have been related to the skin irritation, no substance related differences from controls were reported in the low dose group.
According to the systemic effects observed, 244 mg/kg bw and 975 mg/kg bw correspond to the NOAEL and LOAEL of this dermal study.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Embora a ECHA disponibilize muito material em linha na sua língua, uma parte desta página está disponível apenas em inglês. Mais informações sobreas práticas de multilinguismo da ECHA.
Bem-vindo ao sítio Web da ECHA O navegador Internet Explorer 7 (e versões anteriores) não é totalmente suportado por este sítio Web. Por favor atualize o seu Internet Explorer para uma versão mais recente.
Este sítio Web utiliza cookies a fim de garantir a melhor experiência possível nos nossos sítios Web.
Saiba mais sobre como utilizar cookies.